ArticleTheranostics2018

Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.

Chuan Xing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.